Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis

OBJECTIVE: To characterize changes in myeloid and lymphoid innate immune cells in patients with relapsing-remitting multiple sclerosis (MS) during a 6-month follow-up after alemtuzumab treatment. METHODS: Circulating innate immune cells including myeloid cells and innate lymphoid cells (ILCs) were a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gross, Catharina C., Ahmetspahic, Diana, Ruck, Tobias, Schulte-Mecklenbeck, Andreas, Schwarte, Kathrin, Jörgens, Silke, Scheu, Stefanie, Windhagen, Susanne, Graefe, Bettina, Melzer, Nico, Klotz, Luisa, Arolt, Volker, Wiendl, Heinz, Meuth, Sven G., Alferink, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063395/
https://www.ncbi.nlm.nih.gov/pubmed/27766281
http://dx.doi.org/10.1212/NXI.0000000000000289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063395/
https://www.ncbi.nlm.nih.gov/pubmed/27766281
http://dx.doi.org/10.1212/NXI.0000000000000289

Ejemplares similares